WGS
XBI icon

Washington Growth Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Washington Growth Strategies’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
10,268
+47
+0.5% +$6.35K 0.9% 25
2026
Q1 		$1.31M Sell
10,221
-690
-6% -$86.1K 0.85% 25
2025
Q4 		$1.33M Hold
10,911
– – 0.86% 24
2025
Q3 		$1.09M Sell
10,911
-605
-5% -$54.5K 0.78% 24
2025
Q2 		$955K Buy
11,516
+11,435
+14,117% +$912K 0.73% 24
2025
Q1 		$934 Buy
+81
New +$7.24K 0.84% 21
2024
Q3 		$14.5K Buy
+1,409
New +$138K 0.55% 21

Other funds holding XBI

MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
WAM
Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
NHFG
New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return
RAM
Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

Washington Growth Strategies's XBI Position: Q2 2026 in Review

Washington Growth Strategies increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.46% in Q2 2026, buying an estimated $6.35K and bringing the position to 10,268 shares worth $1.62M. The position accounts for 0.9% of the portfolio, ranked #25.

Washington Growth Strategies first reported a position in XBI in Q3 2024 and has held it in 7 quarters since. 349 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Washington Growth Strategies held 10,268 shares of State Street SPDR S&P Biotech ETF worth $1.62M as of Q2 2026.
  • Washington Growth Strategies bought 47 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.35K.
  • State Street SPDR S&P Biotech ETF made up 0.9% of Washington Growth Strategies's portfolio in Q2 2026, its #25 holding.
  • Washington Growth Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 7 quarters since.
  • 349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Washington Growth Strategies's 13F filing for Q2 2026, filed 16 Jul 2026.